NASDAQ · NXLHealthcareElectromedical Equipment

Nexalin Technology financials

$4.35+1.87%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
Revenue$301.6K$168.7K$110.7K$1.3M
Gross profit$240.3K$132.1K$85.1K$958.1K
Gross margin79.7%78.3%76.8%72.5%
Operating income-$8.4M-$7.8M-$5.7M-$1.8M
Net income-$8.2M-$7.6M-$4.6M-$1.7M
Net margin−2725.4%−4511.6%−4197.6%−128.5%
Diluted EPS$-15.00$-24.90$-18.90$-9.00
EBITDA-$8.4M-$7.7M-$5.7M-$1.8M
Operating cash flow-$5.0M-$3.9M-$3.8M-$2.2M
Free cash flow-$5.0M-$3.9M-$3.8M-$2.2M
Diluted shares0.5M0.3M0.2M0.2M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31
Cash & equivalents$654.8K$574.5K$580.2K$162.7K
Short-term investments$3.1M$2.9M$2.4M$6.8M
Total debt$0.00$0.00$0.00$700.0K
Total assets$4.6M$4.2M$3.6M$7.4M
Total liabilities$887.3K$546.7K$425.3K$2.0M
Shareholders' equity$3.7M$3.7M$3.2M$5.5M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology